The opioid epidemic in the United States has accelerated during the COVID-19 pandemic. Over 81,000 drug overdose deaths occurred between June 2019 and May 2020-the highest ever recorded in a one-year period (The Centers for Disease Control and Prevention, 2020). Meanwhile, 17 states have legalized recreational cannabis. Over a third of the U.S. population now lives in a state with a recreational cannabis law (RCL) (ProCon.Org, 2021; U.S. Census Bureau, 2021).RCLs were not originally adopted to mitigate the opioid epidemic, though they may have the potential to reduce opioid use. Recent empirical evidence suggests cannabis is a substitute for prescription opioids in pain management (Shi et al., 2019;Wen & Hockenberry, 2018;Wen et al., 2021). In addition, there is some clinical evidence suggesting cannabis may mitigate opioid withdrawal symptoms (Wiese & Wilson-Poe, 2018). These findings are promising because RCLs, unlike medical cannabis laws (MCLs), make cannabis available to the entire population and thus have a larger imspact on cannabis use (Hollingsworth et al., 2020). However, cannabis does not directly treat the symptoms of opioid use disorder, for which medications for opioid use disorder are the only clinically effective treatment.